Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Confirmed diagnosis of T2DM by standard criteria.~* Treatment with oral anti-diabetic therapy, on stable dose for at least 12 weeks prior to the screening visit. Acceptable background anti-diabetic therapy includes: metformin (≥ 1500 mg) as monotherapy or in combination with SU, TZDs, or glinides~* Age: ≥18 to ≤ 80 years~* HbA1c of ≥ 7.5 and ≤ 11.0%~* Body Mass Index (BMI) ≥22 to ≤45 kg/m2~Exclusion criteria:~* FPG ≥ 270 mg/dL (≥ 15.0 mmol/L)~* Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months~* Any of following within past 6 months: Myocardial infarction, TIA or stroke, coronary artery bypass surgery or percutaneous coronary intervention~* History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes~* Acute infections which may affect blood glucose control within 4 weeks prior to screening Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (metformin + glimepiride) (Type: EXPERIMENTAL): None
- Placebo (metformin + glimepiride) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).